Adverse Reactions of Selective Serotonin Reuptake Inhibitors
- Dr Olav Spigset
- … show all 1 hide
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are extensively used in the treatment of depression, panic disorder and obsessive-compulsive disorder, and are now being evaluated in the treatment of a number of other psychiatric disorders. The aim of this study was to investigate the pattern of adverse reactions reported on SSRIs in Sweden and assess possible risk factors associated with the occurrence of adverse reactions to these agents.
A survey was made of 1202 reports describing 1861 adverse reactions to SSRIs submitted to the Swedish Adverse Drug Reactions Advisory Committee.
The most often reported adverse reactions were neurological symptoms (22.4%), psychiatric symptoms (19.5%) and gastrointestinal symptoms (18.0%); however, dermatological symptoms (11.4%) and general symptoms (9.8%) were also frequent. Compared with other drugs, gastrointestinal symptoms were more often reported for fluvoxamine, psychiatric symptoms were more often reported for sertraline and dermatological symptoms were more often reported for fluoxetine. In total, the diagnoses most frequently reported were nausea (n = 139), rash (n = 90), anxiety (n = 84), paraesthesias (n = 69), headache (n = 63) and diarrhoea (n = 63).
Parkinsonism, confusion, hallucinations, euphoria, hyponatraemia, bradycardia and hypotension were more often reported in the elderly, whereas urticaria, akathisia, and haematological, endocrinological, sexual and some visual reactions were more often reported in individuals who were younger than average. Dermatological reactions, fatigue, hyponatraemia and cough were more common in women, whereas dyskinesias/akathisia and aggression more often were seen in men.
The median SSRI dosages were above average in patients experiencing seizures, hypomania/mania, personality changes, malaise, bodyweight gain, gynaecomastia and hyperprolactinaemia/galactorrhoea. Severe symptoms, such as seizures, hyponatraemia and the serotonin syndrome, were rarely reported.
Although the design of the study makes it difficult to draw conclusions about causality, a variety of adverse reactions were reported. Therefore, the awareness that a particular symptom in a patient treated with an SSRI might be an adverse reaction should be high.
- Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–7 CrossRef
- Borg S, Brodin K. Antidepressant drugs. In: Dukes MNG, editor. Meyler’s side effects of drugs. 12th ed. Amsterdam: Elsevier, 1992: 30–78
- Spigset O, Hedenmalm K, Dahl M-L, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96: 379–84 CrossRef
- Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone excretion (SIADH) induced by psychotropic drugs. Drug Saf 1995; 12: 209–225 CrossRef
- Sporer KA. The serotonin syndrome. Drug Saf 1995; 13: 94–104 CrossRef
- WHO collaborating centre for drug statistics methodology. Guidelines for defined daily doses (DDD). Oslo: WHO collaborating centre for drug statistics methodology, 1991: 76
- WHO collaborating centre for drug statistics methodology. Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDD) for plain substances. Oslo: WHO collaborating centre for drug statistics methodology, 1997
- Wiholm B-E, Olsson S, Moore N, et al. Spontaneous reporting systems outside the United Sates. In: Strom BL, editor. Pharmacoepidemiology. 2nd ed. Chichester: John Wiley and Sons, 1994: 139–55
- Dukes MNG. The importance of adverse reactions in drug regulation. Drug Saf 1990; 5: 3–6 CrossRef
- Rawlins MD. Spontaneous reporting of adverse drug reactions. Br J Clin Pharmacol 1988; 26: 1–5 CrossRef
- Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16: 373–8 CrossRef
- Haffmans PMJ, Timmerman L, Hoogduin CAL, and the LUCIFER group. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 1996; 11: 157–64 CrossRef
- De Vilde J, Spiers R, Mertens C, et al. A double blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87: 141–5 CrossRef
- Pinder RM. Mianserin: pharmacological and clinical correlates. Nord J Psychiatr 1991; 45 Suppl. 24: 13–26 CrossRef
- Stahl MMS, Lindquist M, Petterson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–9 CrossRef
- Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12–6 CrossRef
- Mitchelson F. Pharmacological agents affecting emesis: a review (part I). Drugs 1992; 43: 295–315 CrossRef
- Lance W, Lambert GA, Goadsby PJ et al. 5-hydroxytryptamine and its putative aetiological involvement in migraine. Cephalalgia 1989; 9 Suppl. 9: 7–13
- Riedel W, van Praag HM. Avoiding and managing anticholinergic effects of antidepressants. CNS Drugs 1995; 3: 245–59 CrossRef
- Bertilsson L, Dahl M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 3: 200–23 CrossRef
- Adverse Reactions of Selective Serotonin Reuptake Inhibitors
Volume 20, Issue 3 , pp 277-287
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Dr Olav Spigset (1) (2)
- Author Affiliations
- 1. Adverse Drug Reactions Monitoring Center, Division of Clinical Pharmacology, Norrland University Hospital, Umeå, Sweden
- 2. Department of Clinical Pharmacology, Regional and University Hospital, Trondheim, N-7006, Norway